Clinical Trial Update: A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA [Phase 2]

View source ↗

Summary

Phase 2 trial investigating intensive uric acid lowering therapy (RDEA3170, febuxostat, dapagliflozin) on urinary excretion of uric acid in asymptomatic hyperur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asymptomatic Hyperuricemia

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• FEBUXOSTAT (Febuxostat)
• RDEA3170 (RDEA3170)

Snippet

Sponsor: AstraZeneca | Conditions: Asymptomatic Hyperuricemia | Phase 2 | Status: COMPLETED | Results posted: 2019-07-18